The genital herpes treatment drugs market will feature magnificent growth at a compounded annual growth rate (CAGR) of 4.9% during the forecast period from 2018 to 2026. According to the latest research citations published by the World Health Organization (WHO), approximately two-thirds of the global population under 50 years of age is infected with herpes simplex virus type 1 (HSV-1).
Genital herpes is contagious and transmitted via the vaginal and anal routes. It is important for any individual to visit a health clinic when symptoms such as small blisters around the thigh, genital, or anal regions are visible. Early symptoms of genital herpes infection include burning sensations and pain during micturition.
The product pipeline is strong with drugs such as GEN-003, a therapeutic vaccine developed by Genocea Biosciences, Inc., currently under phase 3 clinical trial studies with promising results in the reduction of genital lesions. Vical, Inc. is developing VCL-HB01, a therapeutic vaccine that showcases excellent results in the treatment of lesion recurrence.
Market Synopsis
Excellent pharmacodynamic and pharmacokinetic profiles make acyclovir the first-line therapeutic drug for the treatment of genital herpes.
Acyclovir is currently dominating the drug class segment for genital herpes treatment drugs. The key attributes contributing to the dominance of acyclovir are excellent pharmacodynamic and pharmacokinetic parameters. Acyclovir is safe and well tolerated in patients with genital herpes infection, according to clinical studies.
It is the first-line drug therapy due to its ability to inhibit and inactivate HSV-specific DNA polymerase to prevent viral DNA synthesis without causing any harm to normal cellular processes. The recommended dose is 200 mg, taken five times daily for ten days.
Famciclovir will be the fastest-growing antiviral drug during the forecast period of 2018 to 2026. Improved bioavailability of famciclovir is useful in the suppression of recurrent genital herpes infection in immunocompromised patients.
In North America, the rising prevalence of genital herpes drives the market growth.
North America is leading the regional segment for genital herpes treatment drugs. According to Centers for Disease Control and Prevention (CDC) statistics, genital herpes is prevalent in every sixth person aged between 14 and 49 years. The major factors influencing the market's growth in North America are the rising prevalence of genital herpes and the development of diagnostic centers resulting in early diagnosis and medical intervention for treating genital herpes.
In Europe, the market is driven by factors such as the existence of key players such as GlaxoSmithKline, Plc., Novartis AG, AstraZeneca, Plc., etc., and the recent refugee influx from the Levant region has resulted in a steep increase in the genital herpes infection. Asia Pacific is set to become the fastest-growing regional market during the forecast period on account of rising public health awareness regarding sexually transmitted diseases, proactive government policies in curbing the spread of genital herpes infection, and the presence of a huge generic drug market employed for treatment.
Periods of History and Forecast
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market is segmented by drug class and geographical segment.
Pharmaceutical companies providing medication for the treatment of genital herpes infection are AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad Technology, Inc., GlaxoSmithKline, Plc., Mylan N.V., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals, Inc.
Key questions are answered in this report.
Who are the key players competing in the genital herpes treatment drug market?
What is the latest treatment regimen followed by healthcare professionals worldwide for the treatment of genital herpes infection?
What is the disease etiology of genital herpes infection?
What are the drivers, opportunities, and restraints pertaining to the genital herpes treatment drug market?
What is the market performance of acyclovir in the genital herpes treatment drug market?
What will be the compounded annual growth rate of famciclovir in the genital herpes treatment drug market?
Frequently Asked Question:
The market for Genital Herpes Treatment Drugs Market is expected to reach US$ XX in 2026.
The Genital Herpes Treatment Drugs Market is expected to see significant CAGR growth over the coming years, at 4.9%.
The report is forecasted to 2018-2026.
The base year of this report is 2017.
AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad Technology, Inc., GlaxoSmithKline, Plc., Mylan N.V.are some of the major players in the global market.
